

## CALDON BIOTECH INC. Mitochondrial Antibody ELISA

Catalog No. MT073G  
(96 tests)

### NAME AND INTENDED USE

The CALDON BIOTECH INC (CBI), Mitochondrial IgG ELISA is intended for use in the evaluation of patients with suspected primary biliary cirrhosis (PBC).

### SUMMARY AND EXPLANATION OF THE TEST

Mitochondrial Antibodies (MA) are directed against the E2 subunit of the pyruvate dehydrogenase enzyme complex located at the inner mitochondrial membrane (PDC-E2), the E2 subunit of the branched chain 2-oxo acid dehydrogenase complex (BCOADC-E2), the E2 subunit of the 2-oxo-glutarate dehydrogenase complex (OGDC -E2), protein X, and PDC-E1a and PDC-E1. MA are found in ~95% of patients with primary biliary cirrhosis (PBC). MA in low titers are common in chronic active hepatitis and their presence does not preclude response to corticosteroids. MA disappear in about one month after orthotopic liver transplantation (OLT) and decrease with cyclosporine treatment which might be useful in PBC. MA are found in <1% of apparently healthy Caucasoid adults. Approximately 3% of patients with PBC have scleroderma, usually of the CREST syndrome variety. In addition, MA reactive with the PDC -E2 complex are found in some patients with CREST or diffuse scleroderma, sometimes in the absence of overt liver disease. Scleroderma typically precedes PBC in those patients with both diseases.

### PRINCIPLE OF THE TEST

Diluted patient serum is added to wells coated with purified antigen. IgG specific antibody, if present, binds to the antigen. All unbound materials are washed away and the enzyme conjugate is added to bind to the antibody - antigen complex, if present. Excess enzyme conjugate is washed off and substrate is added. The plate is incubated to allow the hydrolysis of the substrate by the enzyme. The intensity of the color generated is proportional to the amount of IgG specific antibody in the sample.

### MATERIALS PROVIDED

- Microwell Strips: Mitochondrial antigen coated wells (12 x 8 x 1 wells)
- Sample Diluent: 1 bottle (22 mL). Ready to use.
- Calibrator: Yellow Cap. (1.50 mL/vial). Ready to use.
- Positive Control: Red Cap. (1.50 mL/vial). Ready to use.
- Negative Control: Blue Cap. (1.50 mL/vial). Ready to use.
- Enzyme Conjugate: 1 bottle (12 mL). Ready to use.
- TMB Substrate: 1 bottle (12 mL). Ready to use.
- Stop Solution: 1N H 2 SO 4 ; 1 bottle (12 mL). Ready to use.
- Wash Concentrate: 1 bottle (50 mL), 20X concentrate.

### STORAGE AND STABILITY

- Store the kit at 2-8°C.
- Keep microwells sealed in a dry bag with desiccants.
- The reagents are stable until expiration of the kit.
- Do not expose test reagents to heat, sun or strong light during storage or usage.

### WARNINGS AND PRECAUTIONS

1. Potential biohazardous materials:  
The calibrator and controls contain human source components which have been tested and found non-reactive for hepatitis B surface antigen as well as HIV antibody with FDA licensed reagents. However, there is no test method that can offer complete assurance that HIV, Hepatitis B virus or other infectious agents are absent. These reagents should be handled at the Biosafety Level 2, as recommended in the Centers for Disease Control/National Institutes of Health manual, "Biosafety in Microbiological and Biomedical Laboratories." 1984.
2. Optimal results will be obtained by strict adherence to the test protocol. Precise pipetting as well as following the exact time and temperature requirements is essential.
3. Do not pipette by mouth. Do not smoke, eat, or drink in the areas in which specimens or kit reagents are handled.
4. The components in this kit are intended for use as an integral unit. The components of different lots should not be mixed.
5. Control sera and sample diluent contain preserved with sodium azide. Sodium azide may react with lead and copper plumbing to form explosive metal azide. On disposal, flush with a large volume of water.

**SPECIMEN COLLECTION AND HANDLING**

1. Collect blood specimens and separate the serum.
2. Specimens may be refrigerated at 2–8°C for up to seven days or frozen for up to six months. Avoid repetitive freezing and thawing of samples.

**PREPARATION FOR ASSAY**

1. Bring all specimens and kit reagents to room temperature (20–25°C) and gently mix.
2. Prepare washing buffer by adding the contents of the bottle (50 mL, 20X Wash concentrate) to 950 mL of distilled or deionized water in one-liter container. Store at room temperature.

**ASSAY PROCEDURE**

1. Place the desired number of coated strips into the holder.

**2. Negative control, positive control, and calibrator are ready to use.**

Prepare 1:21 dilution of test samples, by adding 10 µL of the sample to 200 µL of sample diluent. Mix well.

3. Dispense 100 µL of diluted sera, calibrator and controls into the appropriate wells. For the reagent blank, dispense 100 µL sample diluent in 1A well position. Tap the holder to remove air bubbles from the liquid and mix well. Incubate for 20 minutes at room temperature.

4. Remove liquid from all wells. Repeat washing three times with wash buffer.

5. Dispense 100 µL of enzyme conjugate to each well and incubate for 20 minutes at room temperature.

6. Remove enzyme conjugate from all wells. Repeat washing three times with wash buffer.

7. Dispense 100 µL of TMB substrate solution and incubate for 10 minutes at room temperature.

8. Add 100 µL of 1N H<sub>2</sub>SO<sub>4</sub> to stop reaction.

9. Read O.D. within 30 min at 450 nm using microwell reader.

**CALCULATION OF RESULTS**

1. Check Calibrator Factor (CF) value on the calibrator bottle. This value might vary from lot to lot. Make sure you check the value on every kit.

2. Calculate the cut-off value: Calibrator OD x Calibrator Factor (CF).

3. Calculate the Ab (Antibody) Index of each determination by dividing the O.D. value of each sample by cut-off value.

**Example of typical results:**

Calibrator mean OD = 0.8

Calibrator Factor (CF) = 0.5

Cut-off Value = 0.8 x 0.5 = 0.400

Positive control O.D. = 1.2

Ab Index = 1.2 / 0.4 = 3

Patient sample O.D. = 1.6

Ab Index = 1.6 / 0.4 = 4.0

**QUALITY CONTROL**

The test run may be considered valid provided the following criteria are met:

- The O.D. of the Calibrator should be greater than 0.250.
- The Ab index for Negative control should be less than 0.9.
- The Ab Index for Positive control should be greater than 1.2.

**INTERPRETATION**

The following is intended as a guide to interpretation of MA test results; each laboratory is encouraged to establish its own criteria for test interpretation based on sample populations encountered.

**Antibody Index Interpretation**

<0.9 No detectable MA by ELISA.

0.9-1.1 Borderline positive. Follow-up testing is recommend if clinically indicated.

>1.1 Indicative of Autoimmune diseases.

**LIMITATIONS OF THE TEST**

1. The test results obtained using this kit serve only as an aid to diagnosis and should be interpreted in relation to the patient's history, physical findings and other diagnostic procedures.

2. Lipemic or hemolyzed samples may cause erroneous results.

**PERFORMANCE CHARACTERISTICS****1. Sensitivity and Specificity**

113 patient sera were tested by this MA ELISA and a reference ELISA method.

18 sera were positive and 90 were negative by both methods (96% agreement). The results are summarized below:

	MA ELISA		
	+	-	Total
Reference ELISA	18	3	
+	21		90
-	92		
Total	20	93	
	113		

**2. Precision**

**Intra-Assay Study**

Serum	No. of Replicates	Mean	Standard Deviation	Coefficient of Variation%
1	16	1.67	0.096	5.7
2	16	0.84	0.069	8.2
3	16	0.23	0.016	6.9

**Inter-Assay Study**

Serum	No. of Replicates	Mean	Standard Deviation	Coefficient of Variation%
1	10	1.54	0.118	7.6
2	10	0.81	0.074	9.1
3	10	0.20	0.021	10.5

**REFERENCES**

1. Leung PSC, Coppel RL, Gershwin ME. Mitochondrial autoantibodies. In: Peter JB, Shoenfeld Y, editors. Autoantibodies. Amsterdam: Elsevier Science B.V., 1996:494-500.
2. Van Norstrand MD, Malinchoc M, Lindor KD, et al. Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression. *Hepatology* 1997;25:6-11.
3. Butler P, Hamilton-Miller J, Baum H, Burroughs AK. Detection of M2 antibodies in patients with recurrent urinary tract infection using and ELISA and purified PBC specific antigens. Evidence for a molecular mimicry mechanism in the pathogenesis of primary biliary cirrhosis? *Biochem Mol Biol Int* 1995;35:473-85.
4. Vilagut L, Vila J, Vinas O, Pares A, Gines A, Jimenez de Anta MT, Rodes J. Cross-reactivity of anti-Mycobacterium gordonae antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis. *J Hepatol* 1994;21:673-7.
5. Bunn CC, McMorrow M. Anti-M4 antibodies measured by a sulphite oxidase ELISA in patients with both anticentromere and anti-M2 antibodies. *Clin Exp Immunol* 1995;102:131-6.
6. Omagari K, Rowley MJ, Whittingham S, Jois JA, Byron SL, Mackay IR. Autoantibodies to M2 mitochondrial autoantigens in normal human sera by immunofluorescence and novel assays. *J Gastroenterol Hepatol* 1996;11:610-6. Aug-00